COBRA™: a highly potent conditionally active T cell engager engineered for the treatment of solid tumors

• Main Authors: Anand Panchal (Author), Pui Seto (Author), Russell Wall (Author), Brian J. Hillier (Author), Ying Zhu (Author), Jessica Krakow (Author), Aakash Datt (Author), Elizabeth Pongo (Author), Andisheh Bagheri (Author), Tseng-Hui T. Chen (Author), Jeremiah D. Degenhardt (Author), Patricia A. Culp (Author), Danielle E. Dettling (Author), Maia V. Vinogradova (Author), Chad May (Author), Robert B. DuBridge (Author)
• Format: Book
• Published: Taylor & Francis Group, 2020-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Conditionally active COBRA™ (COnditional Bispecific Redirected Activation) T cell engagers are engineered to overcome the limitations of inherently active first-generation T cell engagers, which are unable to discern between tumor and healthy tissues. Designed to be administered as prodrugs, COBRAs...